APO Research
Talk to an analyst

APO RESEARCH · REPORT

Parkinson Disease Drug

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Selected research

Market Analysis & Forecast

Global Parkinson Disease Drug Market Analysis and Forecast 2026-2032

21 December 2025209 pages

Choose your research edition.

Industry ResearchParkinson Disease Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Parkinson Disease Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Parkinson Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Parkinson Disease Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Parkinson Disease Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.

Report Includes

Read the full market overview

This report presents an overview of global market for Parkinson Disease Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Parkinson Disease Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Parkinson Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Parkinson Disease Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Parkinson Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Parkinson Disease Drug revenue, projected growth trends, production technology, application and end-user industry.

Parkinson Disease Drug Segment by Company

Merck

Akorn

GSK

Novartis

Boehringer Ingelheim

Teva Pharmaceutical

Abbvie

Kyowa Hakko Kirin Pharma

Astellas Pharma

Desitin Arzneimittel

Endo Pharmaceuticals

F.Hoffmann-La Roche

H.Lundbeck

Valeant

Apokyn

Orion

Stada Arzneimittel

US WorldMeds

Bausch Health

Parkinson Disease Drug Segment by Type

Sinemet-CR

Trastal

Madopar

COMT Inhibitor

Other

Parkinson Disease Drug Segment by Application

Under 40 Years Old

40-65 Years Old

Above 65 Years Old

Parkinson Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Parkinson Disease Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Parkinson Disease Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinson Disease Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Parkinson Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Sinemet-CR Major Player Table 3. Trastal Major Player Table 4. Madopar Major Player Table 5. COMT Inhibitor Major Player Table 6. Other Major Player Table 7. Global Parkinson Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Under 40 Years Old Major Player Table 9. 40-65 Years Old Major Player Table 10. Above 65 Years Old Major Player Table 11. Parkinson Disease Drug Industry Trends Table 12. Parkinson Disease Drug Industry Drivers Table 13. Parkinson Disease Drug Industry Opportunities and Challenges Table 14. Parkinson Disease Drug Industry Restraints Table 15. Global Parkinson Disease Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Parkinson Disease Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Parkinson Disease Drug Market Share by Region (2021-2026) Table 18. Global Parkinson Disease Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Parkinson Disease Drug Market Share by Region (2027-2032) Table 20. Global Parkinson Disease Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Parkinson Disease Drug Revenue Market Share by Players (2021-2026) Table 22. Global Parkinson Disease Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Parkinson Disease Drug Key Players Headquarters & Area Served Table 24. Global Parkinson Disease Drug Players, Product Type & Application Table 25. Global Parkinson Disease Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Parkinson Disease Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Parkinson Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Parkinson Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Parkinson Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Parkinson Disease Drug Revenue Market Share by Type (2021-2026) Table 32. Global Parkinson Disease Drug Revenue Market Share by Type (2027-2032) Table 33. Global Parkinson Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Parkinson Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Parkinson Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Parkinson Disease Drug Revenue Market Share by Application (2021-2026) Table 37. Global Parkinson Disease Drug Revenue Market Share by Application (2027-2032) Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Merck Parkinson Disease Drug Product Portfolio Table 42. Merck Recent Development Table 43. Akorn Company Information Table 44. Akorn Business Overview Table 45. Akorn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Akorn Parkinson Disease Drug Product Portfolio Table 47. Akorn Recent Development Table 48. GSK Company Information Table 49. GSK Business Overview Table 50. GSK Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GSK Parkinson Disease Drug Product Portfolio Table 52. GSK Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Novartis Parkinson Disease Drug Product Portfolio Table 57. Novartis Recent Development Table 58. Boehringer Ingelheim Company Information Table 59. Boehringer Ingelheim Business Overview Table 60. Boehringer Ingelheim Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Boehringer Ingelheim Parkinson Disease Drug Product Portfolio Table 62. Boehringer Ingelheim Recent Development Table 63. Teva Pharmaceutical Company Information Table 64. Teva Pharmaceutical Business Overview Table 65. Teva Pharmaceutical Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Teva Pharmaceutical Parkinson Disease Drug Product Portfolio Table 67. Teva Pharmaceutical Recent Development Table 68. Abbvie Company Information Table 69. Abbvie Business Overview Table 70. Abbvie Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Abbvie Parkinson Disease Drug Product Portfolio Table 72. Abbvie Recent Development Table 73. Kyowa Hakko Kirin Pharma Company Information Table 74. Kyowa Hakko Kirin Pharma Business Overview Table 75. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio Table 77. Kyowa Hakko Kirin Pharma Recent Development Table 78. Astellas Pharma Company Information Table 79. Astellas Pharma Business Overview Table 80. Astellas Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Astellas Pharma Parkinson Disease Drug Product Portfolio Table 82. Astellas Pharma Recent Development Table 83. Desitin Arzneimittel Company Information Table 84. Desitin Arzneimittel Business Overview Table 85. Desitin Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Desitin Arzneimittel Parkinson Disease Drug Product Portfolio Table 87. Desitin Arzneimittel Recent Development Table 88. Endo Pharmaceuticals Company Information Table 89. Endo Pharmaceuticals Business Overview Table 90. Endo Pharmaceuticals Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio Table 92. Endo Pharmaceuticals Recent Development Table 93. F.Hoffmann-La Roche Company Information Table 94. F.Hoffmann-La Roche Business Overview Table 95. F.Hoffmann-La Roche Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio Table 97. F.Hoffmann-La Roche Recent Development Table 98. H.Lundbeck Company Information Table 99. H.Lundbeck Business Overview Table 100. H.Lundbeck Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. H.Lundbeck Parkinson Disease Drug Product Portfolio Table 102. H.Lundbeck Recent Development Table 103. Valeant Company Information Table 104. Valeant Business Overview Table 105. Valeant Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Valeant Parkinson Disease Drug Product Portfolio Table 107. Valeant Recent Development Table 108. Apokyn Company Information Table 109. Apokyn Business Overview Table 110. Apokyn Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Apokyn Parkinson Disease Drug Product Portfolio Table 112. Apokyn Recent Development Table 113. Orion Company Information Table 114. Orion Business Overview Table 115. Orion Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. Orion Parkinson Disease Drug Product Portfolio Table 117. Orion Recent Development Table 118. Stada Arzneimittel Company Information Table 119. Stada Arzneimittel Business Overview Table 120. Stada Arzneimittel Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. Stada Arzneimittel Parkinson Disease Drug Product Portfolio Table 122. Stada Arzneimittel Recent Development Table 123. US WorldMeds Company Information Table 124. US WorldMeds Business Overview Table 125. US WorldMeds Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 126. US WorldMeds Parkinson Disease Drug Product Portfolio Table 127. US WorldMeds Recent Development Table 128. Bausch Health Company Information Table 129. Bausch Health Business Overview Table 130. Bausch Health Parkinson Disease Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 131. Bausch Health Parkinson Disease Drug Product Portfolio Table 132. Bausch Health Recent Development Table 133. North America Parkinson Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 134. North America Parkinson Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 135. North America Parkinson Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 136. North America Parkinson Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 137. North America Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. North America Parkinson Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 139. North America Parkinson Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 140. Europe Parkinson Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 141. Europe Parkinson Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 142. Europe Parkinson Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 143. Europe Parkinson Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 144. Europe Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Europe Parkinson Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. Europe Parkinson Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 147. China Parkinson Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 148. China Parkinson Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 149. China Parkinson Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 150. China Parkinson Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 151. Asia Parkinson Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. Asia Parkinson Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. Asia Parkinson Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. Asia Parkinson Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. Asia Parkinson Disease Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 156. Asia Parkinson Disease Drug Revenue by Region (US$ Million) & (2021-2026) Table 157. Asia Parkinson Disease Drug Revenue by Region (US$ Million) & (2027-2032) Table 158. SAMEA Parkinson Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 159. SAMEA Parkinson Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 160. SAMEA Parkinson Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 161. SAMEA Parkinson Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 162. SAMEA Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. SAMEA Parkinson Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 164. SAMEA Parkinson Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Parkinson Disease Drug Image Figure 2. Global Parkinson Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Parkinson Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Sinemet-CR Image Figure 5. Trastal Image Figure 6. Madopar Image Figure 7. COMT Inhibitor Image Figure 8. Other Image Figure 9. Global Parkinson Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Parkinson Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Under 40 Years Old Image Figure 12. 40-65 Years Old Image Figure 13. Above 65 Years Old Image Figure 14. Global Parkinson Disease Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Parkinson Disease Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Parkinson Disease Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Parkinson Disease Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Parkinson Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Parkinson Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Parkinson Disease Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Parkinson Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Parkinson Disease Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Parkinson Disease Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Parkinson Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Parkinson Disease Drug Revenue Share by Type (2021-2032) Figure 27. North America Parkinson Disease Drug Revenue Share by Application (2021-2032) Figure 28. North America Parkinson Disease Drug Revenue Share by Country (2021-2032) Figure 29. United States Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Parkinson Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Parkinson Disease Drug Revenue Share by Type (2021-2032) Figure 34. Europe Parkinson Disease Drug Revenue Share by Application (2021-2032) Figure 35. Europe Parkinson Disease Drug Revenue Share by Country (2021-2032) Figure 36. Germany Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Parkinson Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Parkinson Disease Drug Revenue Share by Type (2021-2032) Figure 46. China Parkinson Disease Drug Revenue Share by Application (2021-2032) Figure 47. Asia Parkinson Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Parkinson Disease Drug Revenue Share by Type (2021-2032) Figure 49. Asia Parkinson Disease Drug Revenue Share by Application (2021-2032) Figure 50. Asia Parkinson Disease Drug Revenue Share by Region (2021-2032) Figure 51. Japan Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Parkinson Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Parkinson Disease Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Parkinson Disease Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Parkinson Disease Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Parkinson Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Sinemet-CR
  • Trastal
  • Madopar
  • COMT Inhibitor
  • Other
Applications
  • Under 40 Years Old
  • 40-65 Years Old
  • Above 65 Years Old
Companies covered
  • Merck
  • Akorn
  • GSK
  • Novartis
  • Boehringer Ingelheim
  • Teva Pharmaceutical
  • Abbvie
  • Kyowa Hakko Kirin Pharma
  • Astellas Pharma
  • Desitin Arzneimittel
  • Endo Pharmaceuticals
  • F.Hoffmann-La Roche
  • H.Lundbeck
  • Valeant
  • Apokyn
  • Orion
  • Stada Arzneimittel
  • US WorldMeds
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Parkinson Disease Drug Market by Type
  3. 1.2.1 Global Parkinson Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Sinemet-CR
  5. 1.2.3 Trastal
  6. 1.2.4 Madopar
  7. 1.2.5 COMT Inhibitor
  8. 1.2.6 Other
  9. 1.3 Parkinson Disease Drug Market by Application
  10. 1.3.1 Global Parkinson Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Under 40 Years Old
  12. 1.3.3 40-65 Years Old
  13. 1.3.4 Above 65 Years Old
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Parkinson Disease Drug Market Dynamics
  1. 2.1 Parkinson Disease Drug Industry Trends
  2. 2.2 Parkinson Disease Drug Industry Drivers
  3. 2.3 Parkinson Disease Drug Industry Opportunities and Challenges
  4. 2.4 Parkinson Disease Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Parkinson Disease Drug Market Perspective (2021-2032)
  2. 3.2 Global Parkinson Disease Drug Growth Trends by Region
  3. 3.2.1 Global Parkinson Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Parkinson Disease Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Parkinson Disease Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Parkinson Disease Drug Revenue by Players
  2. 4.1.1 Global Parkinson Disease Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Parkinson Disease Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Parkinson Disease Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Parkinson Disease Drug Key Players Headquarters & Area Served
  7. 4.4 Global Parkinson Disease Drug Players, Product Type & Application
  8. 4.5 Global Parkinson Disease Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Parkinson Disease Drug Market CR5 and HHI
  11. 4.6.3 2025 Parkinson Disease Drug Tier 1, Tier 2, and Tier 3
5 Parkinson Disease Drug Market Size by Type
  1. 5.1 Global Parkinson Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Parkinson Disease Drug Revenue by Type (2021-2032)
  3. 5.3 Global Parkinson Disease Drug Revenue Market Share by Type (2021-2032)
6 Parkinson Disease Drug Market Size by Application
  1. 6.1 Global Parkinson Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Parkinson Disease Drug Revenue by Application (2021-2032)
  3. 6.3 Global Parkinson Disease Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck Parkinson Disease Drug Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Akorn
  8. 7.2.1 Akorn Company Information
  9. 7.2.2 Akorn Business Overview
  10. 7.2.3 Akorn Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Akorn Parkinson Disease Drug Product Portfolio
  12. 7.2.5 Akorn Recent Developments
  13. 7.3 GSK
  14. 7.3.1 GSK Company Information
  15. 7.3.2 GSK Business Overview
  16. 7.3.3 GSK Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GSK Parkinson Disease Drug Product Portfolio
  18. 7.3.5 GSK Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Parkinson Disease Drug Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Boehringer Ingelheim
  26. 7.5.1 Boehringer Ingelheim Company Information
  27. 7.5.2 Boehringer Ingelheim Business Overview
  28. 7.5.3 Boehringer Ingelheim Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
  30. 7.5.5 Boehringer Ingelheim Recent Developments
  31. 7.6 Teva Pharmaceutical
  32. 7.6.1 Teva Pharmaceutical Company Information
  33. 7.6.2 Teva Pharmaceutical Business Overview
  34. 7.6.3 Teva Pharmaceutical Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
  36. 7.6.5 Teva Pharmaceutical Recent Developments
  37. 7.7 Abbvie
  38. 7.7.1 Abbvie Company Information
  39. 7.7.2 Abbvie Business Overview
  40. 7.7.3 Abbvie Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Abbvie Parkinson Disease Drug Product Portfolio
  42. 7.7.5 Abbvie Recent Developments
  43. 7.8 Kyowa Hakko Kirin Pharma
  44. 7.8.1 Kyowa Hakko Kirin Pharma Company Information
  45. 7.8.2 Kyowa Hakko Kirin Pharma Business Overview
  46. 7.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
  48. 7.8.5 Kyowa Hakko Kirin Pharma Recent Developments
  49. 7.9 Astellas Pharma
  50. 7.9.1 Astellas Pharma Company Information
  51. 7.9.2 Astellas Pharma Business Overview
  52. 7.9.3 Astellas Pharma Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
  54. 7.9.5 Astellas Pharma Recent Developments
  55. 7.10 Desitin Arzneimittel
  56. 7.10.1 Desitin Arzneimittel Company Information
  57. 7.10.2 Desitin Arzneimittel Business Overview
  58. 7.10.3 Desitin Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
  60. 7.10.5 Desitin Arzneimittel Recent Developments
  61. 7.11 Endo Pharmaceuticals
  62. 7.11.1 Endo Pharmaceuticals Company Information
  63. 7.11.2 Endo Pharmaceuticals Business Overview
  64. 7.11.3 Endo Pharmaceuticals Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
  66. 7.11.5 Endo Pharmaceuticals Recent Developments
  67. 7.12 F.Hoffmann-La Roche
  68. 7.12.1 F.Hoffmann-La Roche Company Information
  69. 7.12.2 F.Hoffmann-La Roche Business Overview
  70. 7.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
  72. 7.12.5 F.Hoffmann-La Roche Recent Developments
  73. 7.13 H.Lundbeck
  74. 7.13.1 H.Lundbeck Company Information
  75. 7.13.2 H.Lundbeck Business Overview
  76. 7.13.3 H.Lundbeck Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
  78. 7.13.5 H.Lundbeck Recent Developments
  79. 7.14 Valeant
  80. 7.14.1 Valeant Company Information
  81. 7.14.2 Valeant Business Overview
  82. 7.14.3 Valeant Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Valeant Parkinson Disease Drug Product Portfolio
  84. 7.14.5 Valeant Recent Developments
  85. 7.15 Apokyn
  86. 7.15.1 Apokyn Company Information
  87. 7.15.2 Apokyn Business Overview
  88. 7.15.3 Apokyn Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Apokyn Parkinson Disease Drug Product Portfolio
  90. 7.15.5 Apokyn Recent Developments
  91. 7.16 Orion
  92. 7.16.1 Orion Company Information
  93. 7.16.2 Orion Business Overview
  94. 7.16.3 Orion Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Orion Parkinson Disease Drug Product Portfolio
  96. 7.16.5 Orion Recent Developments
  97. 7.17 Stada Arzneimittel
  98. 7.17.1 Stada Arzneimittel Company Information
  99. 7.17.2 Stada Arzneimittel Business Overview
  100. 7.17.3 Stada Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
  102. 7.17.5 Stada Arzneimittel Recent Developments
  103. 7.18 US WorldMeds
  104. 7.18.1 US WorldMeds Company Information
  105. 7.18.2 US WorldMeds Business Overview
  106. 7.18.3 US WorldMeds Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
  108. 7.18.5 US WorldMeds Recent Developments
  109. 7.19 Bausch Health
  110. 7.19.1 Bausch Health Company Information
  111. 7.19.2 Bausch Health Business Overview
  112. 7.19.3 Bausch Health Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
  114. 7.19.5 Bausch Health Recent Developments
8 North America
  1. 8.1 North America Parkinson Disease Drug Revenue (2021-2032)
  2. 8.2 North America Parkinson Disease Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Parkinson Disease Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Parkinson Disease Drug Revenue by Type (2027-2032)
  5. 8.3 North America Parkinson Disease Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Parkinson Disease Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Parkinson Disease Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Parkinson Disease Drug Revenue by Application (2027-2032)
  9. 8.5 North America Parkinson Disease Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Parkinson Disease Drug Revenue by Country
  11. 8.6.1 North America Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Parkinson Disease Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Parkinson Disease Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Parkinson Disease Drug Revenue (2021-2032)
  2. 9.2 Europe Parkinson Disease Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Parkinson Disease Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Parkinson Disease Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Parkinson Disease Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Parkinson Disease Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Parkinson Disease Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Parkinson Disease Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Parkinson Disease Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Parkinson Disease Drug Revenue by Country
  11. 9.6.1 Europe Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Parkinson Disease Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Parkinson Disease Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Parkinson Disease Drug Revenue (2021-2032)
  2. 10.2 China Parkinson Disease Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Parkinson Disease Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Parkinson Disease Drug Revenue by Type (2027-2032)
  5. 10.3 China Parkinson Disease Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Parkinson Disease Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Parkinson Disease Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Parkinson Disease Drug Revenue by Application (2027-2032)
  9. 10.5 China Parkinson Disease Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Parkinson Disease Drug Revenue (2021-2032)
  2. 11.2 Asia Parkinson Disease Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Parkinson Disease Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Parkinson Disease Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Parkinson Disease Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Parkinson Disease Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Parkinson Disease Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Parkinson Disease Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Parkinson Disease Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Parkinson Disease Drug Revenue by Country
  11. 11.6.1 Asia Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Parkinson Disease Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Parkinson Disease Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Parkinson Disease Drug Revenue (2021-2032)
  2. 12.2 SAMEA Parkinson Disease Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Parkinson Disease Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Parkinson Disease Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Parkinson Disease Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Parkinson Disease Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Parkinson Disease Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Parkinson Disease Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Parkinson Disease Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Parkinson Disease Drug Revenue by Country
  11. 12.6.1 SAMEA Parkinson Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Parkinson Disease Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Parkinson Disease Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst